NCT05657691 is a Phase 2 clinical trial of Xanamem™ in Major Depressive Disorder, sponsored by Actinogen Medical.

Who is sponsoring NCT05657691?

NCT05657691 is sponsored by Actinogen Medical.

What drugs are being tested in NCT05657691?

Interventions in NCT05657691: Xanamem™, Placebo.

What condition does NCT05657691 study?

NCT05657691 studies Major Depressive Disorder, MDD, Cognitive Impairment.

Is NCT05657691 still recruiting?

NCT05657691 is currently completed. Last updated 22 January 2025.

Last reviewed 2025-01-22 · How we verify

NCT05657691

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Xanamem® in Adults With Major Depressive Disorder and Impaired Cognition (XanaCIDD)

Completed Phase 2 Last updated 22 January 2025

What this trial tests

Phase 2 trial testing Xanamem™ in Major Depressive Disorder in 167 participants. Completed in 1 July 2024.

Timeline

28 November 2022

Primary endpoint
1 July 2024

1 July 2024

Quick facts

Lead sponsor	Actinogen Medical
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	167
Start date	28 November 2022
Primary completion	1 July 2024
Estimated completion	1 July 2024
Sites	12 locations across United Kingdom, Australia

Drugs / interventions tested

Xanamem™
Placebo

Conditions studied

Major Depressive Disorder — all drugs for Major Depressive Disorder →
MDD — all drugs for MDD →
Cognitive Impairment — all drugs for Cognitive Impairment →

Sponsor

Actinogen Medical — full company profile →

Who can join

Adults 18 to 75, any sex, with Major Depressive Disorder or MDD. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Xanamem is being developed as a potential treatment for symptomatic, early stages of Alzheimer's Disease (AD) and Major Depressive Disorder (MDD). This XanaCIDD Phase II study in MDD is to investigate the safety and efficacy of Xanamem™ in treating patients with cognitive and depressive symptoms. Trial participants will be randomized to either receive 10mg of Xanamem™ once daily or a Placebo at a 1:1 ratio in a double-blinded fashion.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Contribution of local regeneration of glucocorticoids to tissue steroid pools.
Khan S, Livingstone DEW, Zielinska A, Doig CL, et al · · 2023 · cited 2× · PMID 37343234 · DOI 10.1530/joe-23-0034
PET in neurotherapeutic discovery and development.
Chassé M, Vasdev N. · · 2025 · cited 1× · PMID 39665954 · DOI 10.1016/j.neurot.2024.e00498

Verify or expand the search:

Other trials of Xanamem™

Trials testing the same drug.

NCT02727699 — A Phase II Study to Assess the Safety, Tolerability and Efficacy of Xanamem™ in Subjects With Mild Dementia Due to AD (X · Phase 2 · completed

Other recruiting trials for Major Depressive Disorder

Currently open trials in the same condition.

NCT07219394 — Peer-Delivered Behavioral Activation in a CCBHC · NA · recruiting
NCT06705478 — Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disor · Phase 2 · recruiting
NCT06749392 — An Individual-specific Synchrony Signature · NA · recruiting
NCT07316803 — Group Intervention for Romantic Relationships in Young Adults With Severe Mental Illness · NA · recruiting
NCT07242105 — Optimizing Brain Excitability in Depression · NA · recruiting

Other Actinogen Medical trials

Trials by the same sponsor.

NCT04983368 — A Double-Blind, Placebo-Controlled, Dose Ranging Study of Xanamem® in Healthy Elderly Volunteers · Phase 1, PHASE2 · completed
NCT03830762 — Xanamem™ in Healthy Elderly Subjects · Phase 1 · completed
NCT02727699 — A Phase II Study to Assess the Safety, Tolerability and Efficacy of Xanamem™ in Subjects With Mild Dementia Due to AD (X · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05657691 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Actinogen Medical
Last refreshed: 22 January 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05657691.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing